News and publications
Promethera Biosciences selected to accompany and present during Belgian royal state visit to Japan
Mont-Saint-Guibert, Belgium, October 10, 2016 – Promethera Biosciences SA, a Belgian biotechnology company with U.S. operations developing cell therapies for the treatment of a broad range of liver diseases with high unmet medical needs, today announces that Dr. John Tchelingerian, CEO of Promethera, has been selected to accompany the Belgian economic and academic delegation on a royal state visit to Japan, with HM King Philippe, King of the Belgians and HM Queen Mathilde, Queen of the Belgians.
The Belgian royal visit to Japan is designed to build commercial, economic, political and academic links between the two countries, and increase inter-country trade and investment, specifically focused on the life science, chemical and automotive industries. It also celebrates 150 years of diplomatic and commercial links between Belgium and Japan. The state visit will be from October 11 – 14, and will involve events from Toyko to Nagoya and Osaka.
During this royal state visit to Japan, Dr John Tchelingerian will present Promethera’s business and Japanese activities at the Regenerative Medicine and Cell Therapy workshop during the Innovation Together conference - at the Life Sciences symposium. The conference will be held at the Hotel New Otani in Tokyo, Japan. Promethera’s CEO presentation will be at 14:15 pm, local time) on October 11, 2016. The conference will be attended by the Belgian royal party, as well as other notable Belgian and Japanese, including HE Paul Magnette, Minister-President of Wallonia.
“Promethera Biosciences is honored to have been selected to represent Belgium and accompany the royal state visit to Japan,” said Dr John Tchelingerian, CEO of Promethera Biosciences. “The quality and quantity of Japanese research, manufacturing and investment in regenerative medicine forms the basis for Promethera’s strategic focus on Japan. This includes our plans to expand our product and business development activities in Japan together with the support of our existing Japanese investor MGI Global Fund (Mitsui). We look forward to the potential of attracting new Japanese investors as Promethera continues to develop its regenerative medicine strategy in Japan.”
About Promethera Biosciences
Promethera Biosciences is a clinical stage biopharmaceutical company and the global leader in cell therapy and regenerative medicine for the treatment of inborn and acquired liver diseases with no effective therapeutic cure. Promethera uses allogeneic progenitor cells, stem cells and mature hepatocytes that are harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). These technologies have resulted in the development of three different cell products, HepaStem and H2Stem (progenitor/stem cells) and Heparesc® (mature hepatocytes). Promethera specializes in the development of therapeutic options for the treatment of a broad variety of liver diseases. These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such as a1at deficiency (α1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatits (NASH).
Promethera Biosciences is a spin-off of the Walloon Region-based Université catholique de Louvain (UCL) and was founded in 2009 by Prof. Dr. Etienne Sokal and Sopartec, the tech transfer office (TTO) of UCL. Promethera is headquartered in Mont-Saint-Guibert, Belgium with a U.S. based GMP compliant manufacturing facility in Durham, NC, US. For more information, visit www.promethera.com
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01